NDA 021024 · Sanofi Aventis US
Priftin
Rifapentine · Oral · Rifamycin Antimycobacterial
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Jun 22, 1998
Approved uses
4
Original approval plus efficacy supplements
Registered trials
68
25 Phase 3, 10 recruiting
FAERS reports
526
379 serious, 15 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 6, 2026.
PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. ( 1.1 ) PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. tuberculosis in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. ( 1.2 ) See Full Prescribing Information for Limitations of Use. ( 1.1 , 1.2 ) 1.1 Active Pulmonary Tuberculosis PRIFTIN ® (rifapentine) is indicated in adults and pediatric patients 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis . PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . Limitations of Use Do not use PRIFTIN monotherapy in either the initial or the continuation phases of active antituberculous treatment. PRIFTIN should not be used once weekly in the continuation phase regimen in combination with isoniazid (INH) in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (RIF)-resistant organisms [see Warnings and Precautions (5.4) and Clinical Studies (14.1) ] . PRIFTIN has not been studied as part of the initial phase treatment regimen in HIV-infected patients with active pulmonary tuberculosis. 1.2 Latent Tuberculosis Infection PRIFTIN is indicated in adults and pediatric patients 2 years and older for the treatment of latent tuberculosis infection caused by Mycobacterium...
Mechanism: Rifapentine, a cyclopentyl rifamycin, is an antimycobacterial agent [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 25, 2014 Supplement 11 · Efficacy · priority review LetterMedication GuidePediatric Medical Review
- Jun 1, 2009 Supplement 8 · Efficacy LetterLabelReview
- Oct 20, 2000 Supplement 5 · Efficacy ReviewLetterLabel
- Jun 22, 1998 Original approval · Type 1 - New Molecular Entity · priority review ReviewLetterLabel
1 products under this application
- PRIFTIN · RIFAPENTINE 150MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rifapentine" as an intervention, any sponsor and status, largest first.
- BCG Revaccination in Children and AdolescentsPivotal-lookingSuspended
Tuberculosis Research Centre, IndiaGovernment (non-federal)
NCT05330884 · 9,200 participants (planned) · Start Jul 15, 2024 · Primary completion Jun 2027
Drug: BCG vaccine; Oral Chemoprophylaxis · For: Tuberculosis Infection; Tuberculosis
Sites: Chennai, India
- Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis InfectionPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00023452 · 8,053 participants · Start Jun 2001 · Primary completion Oct 2010
Drug: RPT + INH once weekly for 3 months given by DOT; Isoniazid (INH) daily for 9 months · For: Tuberculosis
Sites: Little Rock, Arkansas; Los Angeles, California; San Diego, California · 26 sites in all
- Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive IndividualsPivotal-lookingCompleted
The Aurum Institute NPCAcademic, hospital or other
NCT02980016 · 4,027 participants · Start Nov 2016 · Primary completion Oct 18, 2019
Drug: rifapentine + isoniazid; Isoniazid · For: Tuberculosis; HIV
Sites: Johannesburg, South Africa
- A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)Pivotal-lookingRecruiting
Huashan HospitalAcademic, hospital or other
NCT06022146 · 3,520 participants (planned) · Start Sep 1, 2023 · Primary completion Sep 1, 2026
Drug: isoniazid and rifapentine; Rifampin and Isoniazid · For: Tuberculosis; Latent Tuberculosis
Sites: Anshun, China; Bijie, China; Daozhen Klau and Hmong Autonomous County in Zun'yi, China · 66 sites in all
- Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBIPivotal-lookingRecruiting
Centers for Disease Control and PreventionFederal agency
NCT03474029 · 3,400 participants (planned) · Start Aug 1, 2019 · Primary completion Dec 31, 2029
Drug: Rifapentine daily for 6 weeks; Rifapentine and Isoniazid weekly for 12 weeks and 2 more · For: Latent Tuberculosis
Sites: Denver, Colorado; Washington D.C., District of Columbia; Manhattan, New York · 21 sites in all
- Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes MellitusPivotal-lookingStatus unknown
Dr. Nyanda Elias NtinginyaGovernment (non-federal)
NCT04600167 · 3,000 participants (planned) · Start Jun 17, 2022 · Primary completion Dec 2025
Drug: Isoniazid and Rifapentine (INH-RPT); Placebo · For: Diabetes Mellitus; Tuberculosis
Sites: Mbeya, Tanzania; Moshi, Tanzania; Kampala, Uganda · 4 sites in all
Affiliated Hospital of Nantong UniversityAcademic, hospital or other
NCT07811518 · 3,000 participants (planned) · Start Aug 15, 2022 · Primary completion Aug 31, 2026
Drug: tuberculosis preventive treatment · For: Latent Tuberculosis Infection (LTBI); Tuberculosis (TB)
Sites: Nantong, China; Meishan, China
- Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01404312 · 3,000 participants · Start May 23, 2012 · Primary completion Nov 14, 2017
Drug: Rifapentine (RPT); Isoniazid (INH) · For: Tuberculosis; HIV Infections
Sites: La Jolla, California; Los Angeles, California; San Diego, California · 45 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction67
- pyrexia66
- nausea52
- fatigue48
- vomiting44
- hypertension40
- off label use40
- headache32
- rash32
- dizziness31
- dyspnoea31
- influenza like illness27
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 8 |
| 2013 | 15 |
| 2014 | 16 |
| 2015 | 20 |
| 2016 | 10 |
| 2017 | 73 |
| 2018 | 60 |
| 2019 | 50 |
| 2020 | 19 |
| 2021 | 58 |
| 2022 | 29 |
| 2023 | 13 |
| 2024 | 32 |
| 2025 | 73 |
| 2026 | 45 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Resolved · updated Aug 6, 2026
Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Priftin (Rifapentine)
2024 spending
$552K
Beneficiaries
1,697
2,888 claims
Per beneficiary
$325
$4.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $227,358 |
| 2021 | $296,715 |
| 2022 | $280,673 |
| 2023 | $420,148 |
| 2024 | $551,921 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Chang VK, Imperial MZ, Phillips PPJ, et al. · Nat Commun 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.
Sterling TR, Njie G, Zenner D, et al. · MMWR Recomm Rep 2020 · Systematic Review
- Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management.
MacDougall C, Canonica T, Keh C, et al. · Pharmacotherapy 2022 · Systematic Review
- One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Swindells S, Ramchandani R, Gupta A, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Pettit AC, Phillips PPJ, Kurbatova E, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.